Sökning: id:"swepub:oai:DiVA.org:uu-519801" >
Soluble CD163 predi...
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma
-
- Nikkarinen, Anna (författare)
- Uppsala University,Uppsala universitet,Cancerprecisionsmedicin,Ingrid Glimelius
-
- Lokhande, Lavanya (författare)
- Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments
-
- Amini, Rose-Marie (författare)
- Uppsala University,Uppsala universitet,Cancerimmunterapi,Rose-Marie Amini
-
visa fler...
-
- Jerkeman, Mats (författare)
- Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund
-
- Porwit, Anna (författare)
- Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Molin, Daniel, 1969- (författare)
- Uppsala University,Uppsala universitet,Cancerimmunterapi,Gunilla Enblad
-
- Enblad, Gunilla (författare)
- Uppsala University,Uppsala universitet,Cancerimmunterapi,Gunilla Enblad
-
- Kolstad, Arne (författare)
- Innlandet Hosp Trust Div Gjovik, Dept Oncol, Lillehammer, Norway.,Innlandet Hospital Trust
-
- Raety, Riikka (författare)
- Helsinki Univ Hosp, Comprehens Canc Ctr, Dept Hematol, Helsinki, Finland.,Helsinki University Central Hospital
-
- Hutchings, Martin (författare)
- Rigshosp, Dept Haematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
- Weibull, Caroline E. (författare)
- Karolinska Institutet,Karolinska Institute
-
- Hollander, Peter (författare)
- Uppsala University,Uppsala universitet,Cancerimmunterapi,Rose-Marie Amini
-
- Ek, Sara (författare)
- Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments
-
- Glimelius, Ingrid, 1975- (författare)
- Karolinska Institutet,Uppsala University,Karolinska Institute,Uppsala universitet,Cancerprecisionsmedicin,Karolinska Inst, Dept Med, Div Clin Epidemiol, Stockholm, Sweden.,Ingrid Glimelius
-
visa färre...
-
(creator_code:org_t)
- American Society of Hematology, 2023
- 2023
- Engelska.
-
Ingår i: Blood Advances. - : American Society of Hematology. - 2473-9529 .- 2473-9537. ; 7:18, s. 5304-5313
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed toward the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way to assess the abundance of M2 macrophages is by measuring the level of soluble CD163 in serum (sCD163). We aimed to investigate the prognostic value of sCD163 in 131 patients with MCL. We found that high sCD163 at diagnosis was associated with shorter progression-free survival (PFS) and shorter overall survival (OS) in 81 patients who were newly diagnosed and subsequently treated with chemoimmunotherapy. The same was seen in a cohort of 50 patients with relapsed MCL that were mainly treated within the phase 2 Philemon-trial with rituximab, ibrutinib, and lenalidomide. In patients who were newly diagnosed and had low levels of sCD163, 5-year survival was 97%. There was a moderate correlation between sCD163 and tissue CD163. The association with a poor prognosis was independent of MCL international prognostic index, Ki67, p53 status, and blastoid morphology, as assessed in a multivariable Cox proportional hazards model. In this study, high sCD163 was associated with both shorter PFS and shorter OS, showing that high levels of the M2 macrophage marker sCD163 is an independent negative prognostic factor in MCL, both in the chemoimmunotherapy and ibrutinib/lenalidomide era. In addition, low sCD163 levels identify patients with MCL with a very good prognosis.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nikkarinen, Anna
-
Lokhande, Lavany ...
-
Amini, Rose-Mari ...
-
Jerkeman, Mats
-
Porwit, Anna
-
Molin, Daniel, 1 ...
-
visa fler...
-
Enblad, Gunilla
-
Kolstad, Arne
-
Raety, Riikka
-
Hutchings, Marti ...
-
Weibull, Carolin ...
-
Hollander, Peter
-
Ek, Sara
-
Glimelius, Ingri ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Blood Advances
- Av lärosätet
-
Uppsala universitet
-
Lunds universitet
-
Karolinska Institutet